Create Account | Sign In: Author or Forum

Search Symptoms

Category: Internal Medicine | Nephrology | Journal

Back to Journal Articles

New Technique Allows Rapid Bedside Measurement of GFR

Last Updated: June 29, 2018.

A visible fluorescent injectate-based approach for direct measurement of glomerular filtration rate is accurate with high reproducibility, according to a study published in the June issue of the Journal of the American Society of Nephrology.

FRIDAY, June 29, 2018 (HealthDay News) -- A visible fluorescent injectate (VFI)-based approach for direct measurement of glomerular filtration rate (mGFR) is accurate with high reproducibility, according to a study published in the June issue of the Journal of the American Society of Nephrology.

Dana V. Rizk, M.D., from the University of Alabama at Birmingham, and colleagues developed a new biomarker, VFI, consisting of a 150-kD rhodamine derivative and 5-kD fluorescein carboxymethylated dextrans. VFI-based mGFR values were compared with values obtained by measuring iohexol plasma disappearance in a study involving 16 adults with normal kidney function, eight with chronic kidney disease (CKD) stage 3, and eight with CKD stage 4. VFI-based mGFR required three blood draws over three hours, while five samples taken over six hours were required for iohexol-based mGFR. Repeat VFI injections at 24 hours were received by eight healthy participants.

The researchers found that in all participants, there were close linear correlations for VFI-based mGFR values with the iohexol-based mGFR values. The injections were tolerated well, even when they were given on consecutive days. There were no reports of serious adverse events. There was high reproducibility for VFI-based mGFR.

"The VFI-based approach allows for the rapid determination of mGFR at the bedside while maintaining patient safety and measurement accuracy and reproducibility," the authors write.

Several authors disclosed ties to FAST Biomedical; one author disclosed ties to TdB Consultancy, which collaborates with FAST BioMedical on dextran development. One author was employed by ICON Early Phase Services LLC.

Abstract
Full Text (subscription or payment may be required)


Previous: Weight Loss Linked to Reversal of Atrial Fibrillation Progression Next: AMA Calls for Electronic Health Record Training

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: